Transplant/Cell Therapy - Peds BMT - Clinical Investigator

Loma Linda University Health (Loma Linda University Cancer Center, Loma Linda University School of Medicine and Loma Linda University Faculty Medical Group), Division of Transplant and Cell Therapy (TCT)/Hematological Malignancies is looking to recruit for faculty positions at open rank (Assistant/Associate/Professor) as clinical investigators, including leadership opportunities to join our team.

We are seeking an energetic, faculty clinical investigators who desire to develop an academic, clinical research and patient-centered program, in close collaboration with established basic and translational scientists at Loma Linda University.

Successful candidate will have a primarily clinical assignment, but will also be expected to develop, conduct, and participate in clinical trials, other collaborative research in blood and marrow transplantation, and cellular immunotherapy.

Loma Linda University has a strong collaborative, mentoring and supportive environment especially for graduating fellows and junior faculty applicants.

Teaching responsibilities would involve oversight of residents, fellows, and mid-level providers during ambulatory and inpatient activities,

In addition to standard therapies, TCT/Hem Malignancies Division is focused on the development and implementation of novel therapies for Hematological Malignancies including novel agents, small molecules inhibitors, immune therapies (CAR-T, cell based therapies MoAbs, vaccine, and gene therapy) as well as autologous and allogeneic hematopoietic stem-cell transplantation for malignant and non-malignant diseases.

Specific hematological disease and treatment modality focus is optional and is based on candidate preference.

This work is supported by the Cancer Center Clinical Trials Unit, dedicated clinic space and infusion centers, inpatient unit, a new cGMP and TCT laboratory, FACT accredited TCT program in pediatric autologous and allogeneic BMT and immune effector cell therapy, fully characterized tumor samples repository and new state-of-the-art Children Hospital building opened in 2021, all on the Medical School campus.

Loma Linda University was established in 1905. Loma Linda University Children Hospital is the major and only Children Hospital in the Inland Empire in Southern California that provides Transplant and Cell therapy for Children.

Qualification’s requirements include MD (or equivalent), completion of fellowships in Pediatric Hematology/Oncology or Immunology, TCT fellowship (or equivalent experience) is preferred and Pediatric Hematology/Oncology or Immunology board eligible or certified.

Comprehensive salary, benefits, and a competitive package will be provided, and academic appointment will be commensurate with experience and qualifications. Administrative and research support including staff, resources and infrastructure will be provided.

The campus is located within driving distance from Los Angeles, beach cities and San Diego.

Interested candidates should submit inquiries to Division Head: Hisham Abdel-Azim, MD ( )

LLHU values diversity and is committed to equal opportunity in employment.

Compensation & Benefits

The compensation range listed is for starting base compensation only and is adjusted based upon years of experience and/or faculty rank: $200,000 – $500,000. This amount does not include variable compensation or extra productivity and is subject to the individual department compensation plans. More information on compensation is discussed with the departments during the recruitment process.
Our benefits include:

• Generous Retirement Contribution
• Comprehensive Medical/Dental Coverage
• Competitive Vacation & Sick Days
• CME Days and Funds
• Relocation Assistance (if applicable)
• Paid Malpractice Insurance
• Paid Life Insurance
• Federal Loan Repayment (If eligible)

Physician Loan Repayment:

For more information on Loan Forgiveness, please click on the links below:

We are a California Employer - Please note that a California residency is required upon start date.

This opportunity is not eligible for a Conrad 30 waiver.